List view / Grid view
Submission based on the two largest comparative phase 3 clinical…
9 January 2014 | By Daiichi Sankyo
Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism...
Daiichi Sankyo is seeking approval for edoxaban for the prevention…
8 January 2014 | By Daiichi Sankyo
Daiichi Sankyo is seeking approval for edoxaban for the prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation...
Daiichi Sankyo is seeking approval in Japan for edoxaban in…
19 December 2013 | By Daiichi Sankyo Company
Daiichi Sankyo is seeking approval in Japan for edoxaban in new indications for non-valvular atrial fibrillation (AF) and symptomatic venous thromboembolism...
Daiichi Sankyo announced results from the global phase 3 Hokusai-VTE…
1 September 2013 | By Daiichi Sankyo
Daiichi Sankyo announced results from the global phase 3 Hokusai-VTE study...
Results of the PRASFIT-ACS study...
16 March 2013 | By Daiichi Sankyo
Results of the PRASFIT-ACS study...
Daiichi Sankyo & Amplimmune have entered into a broad strategic…
8 January 2013 | By Daiichi Sankyo
Daiichi Sankyo & Amplimmune have entered into a broad strategic collaboration...
Edoxaban is an investigational, once daily, novel oral factor Xa…
25 October 2012 | By Daiichi Sankyo
Edoxaban is an investigational, once daily, novel oral factor Xa inhibitor...
Study did not meet primary objective of demonstrating prasugrel superiority…
26 August 2012 | By Eli Lilly and Company
Study did not meet primary objective of demonstrating prasugrel superiority over clopidogrel in this patient population...
ArQule and Daiichi Sankyo announced that recruitment of patients has…
18 May 2012 | By Daiichi Sankyo
ArQule and Daiichi Sankyo announced that recruitment of patients has been completed...
First-in-class treatment option soon available to treat deadly form of…
17 August 2011 | By Daiichi Sankyo
First-in-class treatment option soon available to treat deadly form of skin cancer...
